FDA accepts Iroko's Zorvolex sNDA for review

The US Food and Drug Administration (FDA) is to review Iroko Pharmaceuticals' supplemental new drug application (sNDA) for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug (NSAID) for treating osteoarthritis pain in adults.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news